Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Steven G. DuBois"'
Autor:
Ajami Gikandi, Susan N. Chi, Kee Kiat Yeo, Allison F. O'Neill, David S. Shulman, Steven G. DuBois, Natalie B. Collins
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Immune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off‐label use of ICI in pediatrics remain unclear. Method
Externí odkaz:
https://doaj.org/article/c0b09fda39d84998acabc99d862c2cad
Autor:
David S. Shulman, Priscilla Merriam, Edwin Choy, Lillian M. Guenther, Kerri L. Cavanaugh, Pei‐Chi Kao, Andrew Posner, Ketki Bhushan, Grace Fairchild, Emma Barker, Kelly Klega, Kimberly Stegmaier, Brian D. Crompton, Wendy B. London, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 15207-15216 (2023)
Abstract Background Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin‐dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF‐1R inhibition in precl
Externí odkaz:
https://doaj.org/article/87f07bdc01a54de09d41b110e52c7544
Autor:
Raja Shaikh, Brent R. Weil, Christopher B. Weldon, Nan Chen, Wendy B. London, Morgan Krush, Megan Anderson, Mark Gebhardt, Alanna J. Church, Steven G. DuBois, Yana Pikman, Jennifer Spidle, Catherine B. Wall, Angela Feraco, Nicole J. Ullrich, Jennifer W. Mack, Elizabeth Mullen, Junne Kamihara, Suzanne Forrest, Suzanne Shusterman, Katherine A. Janeway, Ahmad Alomari, Horacio Padua, Carlos Rodriguez‐Galindo, Allison F. O'Neill
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13300-13308 (2023)
Abstract Background Pediatric interventional oncology (PIO) is a growing field intended to provide additional or alternative treatment options for pediatric patients with benign or malignant tumors. Large series of patients treated uniformly and subj
Externí odkaz:
https://doaj.org/article/c80b0344ed624477a0354a19d3dcdca0
Autor:
Ellen Zhang, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5517-5525 (2023)
Abstract Purpose The aim of this study was to evaluate the rate of early trial discontinuation of oncology trials and reasons for early termination, to assess potential trends in rates of oncology trial termination, and to perform a comprehensive ana
Externí odkaz:
https://doaj.org/article/f9e6d1c91dcb40c1bf1006580327ec50
Autor:
David S. Shulman, Lulla V. Kiwinda, Stacey Edwards, Catherine M. Clinton, Sarah Hunt, Lianne Greenspan, Kristen D. Lawler, Gregory Reaman, Hasan Al‐Sayegh, Kira Bona, Allison F. O'Neill, Suzanne Shusterman, Katherine A. Janeway, Andrew E. Place, Susan N. Chi, Clement Ma, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2310-2318 (2021)
Abstract Background Single patient Investigational New Drug (IND) applications are one mechanism through which experimental therapies are accessed for children with cancer. The landscape of use, outcomes, and toxicity from single patient INDs remains
Externí odkaz:
https://doaj.org/article/a55985f140e94952817cff413dfa8e6f
Autor:
Leo Mascarenhas, Chitose Ogawa, Theodore W. Laetsch, Brenda J. Weigel, Michael W. Bishop, Julie Krystal, Scott C. Borinstein, Emily K. Slotkin, Jodi A. Muscal, Pooja Hingorani, Donna E. Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 843-856 (2021)
Abstract Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recomm
Externí odkaz:
https://doaj.org/article/728f5f60eab94b5f8c5a384248851207
Autor:
Mir Lim, David S. Shulman, Holly Roberts, Anran Li, Jessica Clymer, Kira Bona, Hasan Al‐Sayegh, Clement Ma, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6658-6666 (2020)
Abstract Background Off‐label drug prescribing is common in pediatric clinical medicine, though the extent and impact of this practice in pediatric oncology has not yet been characterized. Methods We completed a retrospective single‐institution c
Externí odkaz:
https://doaj.org/article/c0eaf4ca092c4d2a8f696014a5e2ee83
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4495-4500 (2020)
Abstract Background The sponsorship mix of trials relevant to young people with cancer has not been reported. Understanding this sponsorship mix may have implications for policies and regulations related to pediatric cancer drug development. Methods
Externí odkaz:
https://doaj.org/article/dd0ae4519f4d4584bb13b3dced57cd6f
Publikováno v:
Sarcoma, Vol 2018 (2018)
Background. As of 2013, the WHO has classified peripheral primitive neuroectodermal tumors (PNETs) within the umbrella of Ewing sarcoma family of tumors (ESFTs) given their shared biology. Histologic features differ between PNET and Ewing sarcoma (ES
Externí odkaz:
https://doaj.org/article/aaa2773d6df040ed90a9534fc43022f1
Autor:
Thomas Cash, Hong Yin, Courtney McCracken, Zhi Geng, Steven G. DuBois, Bahig M. Shehata, Thomas A. Olson, Howard M. Katzenstein, Cynthia Wetmore
Publikováno v:
Sarcoma, Vol 2017 (2017)
Background. Ezrin is a membrane-cytoskeleton linker protein that has been associated with metastasis and poor outcomes in osteosarcoma and high-grade soft tissue sarcomas. The prognostic value of ezrin expression in Ewing sarcoma is unknown. Methods.
Externí odkaz:
https://doaj.org/article/d059f513979348e9b8eb959389b513c1